METSY poster at ICSB-2015
There is a strong trend for weight gain and an increased risk for the onset of type 2 diabetes (T2D) among individuals going through a psychosis. These co-morbidities are related both to treatment side-effects and metabolic changes related to the disease, but their molecular mechanisms are not known. Uncovering the mechanisms could enable the early personalized assessment of the T2D-risk of a psychosis patient, based on metabolomic profiling already before the appearance of the known clinical markers of T2D. In the work presented at ICSB-2015 (http://icsb15.apbionet.org/), we identified metabolomic changes for first-time psychosis patients before the start and at early stages of antipsychotic treatment. Further, we identified associations between these early molecular changes and the later-emerging clinical indicators for the onset of T2D.